Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Immix Biopharma Inc Tangible Asset Value Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The tangible asset value ratio measures the proportion of tangible assets to total assets. It is calculated by dividing the tangible assets by the total assets. This ratio indicates the significance of tangible assets, such as property, plant, and equipment, in the company's total asset structure. A higher ratio suggests a higher proportion of tangible assets relative to total assets.

Immix Biopharma Inc Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.93, a 113.71% change year over year.
Immix Biopharma Inc Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -6.80.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends